Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind active-controlled trial |
Shin, Jonghoon
(SK bioscience)
Teeratakulpisarn, Jamaree (Department of Pediatrics, Khon Kaen University) Puthanakit, Thanyawee (Department of Pediatrics and Center of Excellence in Pediatric Infectious Diseases and Vaccine Faculty of Medicine, Chulalongkorn University) Theerawit, Tuangtip (Department of Pediatrics and Center of Excellence in Pediatric Infectious Diseases and Vaccine Faculty of Medicine, Chulalongkorn University) Ryu, Ji Hwa (SK bioscience) Shin, Jinhwan (SK bioscience) Lee, Seulgi (SK bioscience) Lee, Hayoung (SK bioscience) An, Kyungjun (SK bioscience) Kim, Hun (SK bioscience) |
1 | World Health Organization. Annex 2: Guidelines on evaluation of similar biotherapeutic products (SBPs). WHO Technical Report Series No. 977 [Internet]. Geneva (Switzerland): World Health Organization; 2013 [cited 2018 Aug 30]. Available from: http://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf?ua=1. |
2 | Centers for Disease Control and Prevention. Global pneumococcal disease and vaccine [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2020 [cited 2019 Mar 15]. Available from: https://www.cdc.gov/pneumococcal/global.html. |
3 | Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health 2018;6:e744-57. DOI |
4 | Plotkin SA, Orenstein WA, Offit PA, Edwards KM. Plotkin's vaccines. 7th ed. Philadelphia (PA): Elsevier, 2018:774. |
5 | World Health Organization. Pneumococcus vaccines position paper. 2019 [Internet]. Geneva (Switzerland): World Health Organization; 2019 [cited 2019 Mar 15]. Available from: https://www.who.int/immunization/policy/position_papers/pneumococcus/en/. |
6 | Rodgers GL, Esposito S, Principi N, Gutierrez-Brito M, Diez-Domingo J, Pollard AJ, et al. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. Vaccine 2013;31:4765-74. DOI |
7 | Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis 2018;18:441-51. DOI |
8 | Galanis I, Lindstrand A, Darenberg J, Browall S, Nannapaneni P, Sjostrom K, et al. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J 2016;47:1208-18. DOI |
9 | U.S. Food & Drug Administration. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials [Internet]. Rockville (MD): U.S. Food & Drug Administration; [cited 2019 Mar 15]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-andadolescent-volunteers-enrolled-preventive-vaccine-clinical. |
10 | Scott P, Rutjes AW, Bermetz L, Robert N, Scott S, Lourenco T, et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine 2011;29:9711-21. DOI |
11 | European Medicines Agency. Prevnar 13, Procedure No. EMEA/H/C/001104 [Internet]. Amsterdam (The Netherlands): European Medicines Agency; c1995-2020 [cited 2018 Aug 30]. Available from https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13#authorisationdetails-section. |
12 | Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014;14:839-46. DOI |